The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]
Eric Siemers, MD
Advertisement
Chief medical officer at Acumen Pharmaceuticals.
Articles by Eric Siemers, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players
2
Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia
3
EU Approves Modified-Release Carbidopa/Levodopa Capsules for Parkinson Disease Motor Fluctuations
4
FDA Action Update, August 2026: Approvals, Clearances, and Designations
5